Trial Profile

XALIA LEA- Xarelto for Long-term and Initial Anticoagulation in Venous Thromboembolism (VTE) in Latin America, EMEA and Asia

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rivaroxaban (Primary) ; Fondaparinux sodium; Low molecular weight heparins; Vitamin K antagonists
Indications Deep vein thrombosis; Pulmonary embolism
Focus Adverse reactions
Acronyms XALIA LEA
Sponsors Bayer

Most Recent Events

12 Dec 2017 Results of pooled analysis of the XALIA and XALIA-LEA studies assessing tolerability and efficacy of rivaroxaban in patients with acute venous thromboembolism, were presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
16 Feb 2017 Status changed from active, no longer recruiting to completed.
05 Jan 2017 Planned End Date changed from 1 Mar 2017 to 1 Jan 2017.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com